David A. Siegel Revance Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $24,102 - $48,719	10,300 New	10,300 $26,000
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $10.5 Million - $16 Million	-425,500 Reduced 27.46%	1,124,000 $28.4 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $7.05 Million - $13.5 Million	383,800 Added 32.92%	1,549,500 $49.9 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $12.1 Million - $20.2 Million	658,200 Added 129.69%	1,165,700 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $5.72 Million - $11.4 Million	399,100 Added 368.17%	507,500 $13.7 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $1.25 Million - $2.21 Million	108,400 New	108,400 $1.5 Million
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $1.51 Million - $1.83 Million	-64,600 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $78,982 - $116,619	3,400 Added 5.56%	64,600 $1.62 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $146,160 - $307,980	11,600 Added 23.39%	61,200 $1.5 Million
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $618,016 - $1.38 Million	49,600 New	49,600 $734,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $169,652 - $240,700	-16,600 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$10.67 - $15.49 $209,132 - $303,604	-19,600 Reduced 54.14%	16,600 $215,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $557,480 - $738,118	36,200 New	36,200 $571,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $343,140 - $474,240	-19,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $525,306 - $671,410	-22,306 Reduced 54.0%	19,000 $472,000
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $521,714 - $633,850	19,006 Added 85.23%	41,306 $1.13 Million
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $370,205 - $474,980	12,700 Added 132.29%	22,300 $687,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $235,680 - $348,480	9,600	9,600 $343,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account